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The facilitation of opioid medication is eliciting a nemetic problem since increasing
overdose deaths involve prescription of opioid pain relievers. Chronic painful diseases
require higher doses of opioids, progressively with the development of tolerance
to the antinociceptive effect. Novel strategies for the maintenance of low dosed
opioid effectiveness are necessary to relieve pain and decrease abuse, overdose,
and side effects. N-Palmitoylethanolamine (PEA) is an endogenous compound able
to preserve the homeostasis of the nervous system and to delay the development
of morphine tolerance. In the present study, a preemptive and continuative
treatment with ultramicronized PEA (30 mg/kg, daily, per os) enhanced the acute
antinociceptive efficacy of morphine (10 mg/kg subcutaneously) in rats and prolonged
the responsiveness to the natural opioid. Moreover, PEA-treated animals had a more
rapid recovery from tolerance. Four opioid free days were enough to regain sensitivity
to morphine whereas control animals needed 31 days for full recovery of tolerance.
Characteristically, PEA acquired per se antinociceptive properties in tolerant animals,
suggesting the possibility of an integrated morphine/PEA treatment protocol. To
maintain a significant analgesia, morphine dose had to be increased from 5 up to
100 mg/kg over 17 days of daily treatment. The same pain threshold increase was
achieved in animals using preemptive PEA (30 mg/kg, daily) joined to a combinatorial
acute treatment with morphine (5–20 mg/kg s.c.) and PEA (30–120 mg/kg, p.o.).
Representatively, on day 17, the magnitude of analgesia induced by 100 mg/kg
morphine was obtained by combining 13 mg/kg of morphine with 120 mg/kg of PEA.
PEA strengthens the efficacy and potency of morphine analgesia, allowing prolonged
and effective pain relief with low doses. PEA is suggested in association with morphine
for chronic pain therapies distinguished by low risk of side effects.
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INTRODUCTION
The World Health Organization (WHO) defined the access
to pain treatment a human right (2009). In particular, the
WHO’s recognition of the absolute necessity of opioid analgesics
has reflected the consensus among health experts for decades.
Various other international bodies, such as the United Nations
Economic and Social Council and the World Health Assembly,
have also called on countries to ensure an adequate availability of
opioid analgesics (Lohman et al., 2010).
Today, this indication has been transposed into national law
in several countries increasing opioid prescriptions and quality
of life related to pain relief.
On the other hand, a new phenomenon has arisen. Countries
where the highest percentages of total world consumption of
morphine occurs (North America and Europe) are experiencing
problems related to the facilitation of opioid prescription as
abuse, overdose, and dramatic side effects (Chou et al., 2015;
Rudd et al., 2016a,b; Manchikanti et al., 2017). Persistent
pain conditions, needing chronic therapies, amplify the major
adverse consequences of opioids. The development of tolerance
requires increasing dosages to obtain the same analgesic
effect but generally enhances the severity of side effects as
physical dependence, addiction, fatigue, cognitive dysfunction,
dry mouth, sweating, and weight gain (Jonsson et al., 2010).
Improvement of opioid prescription guidelines, as recently
suggested by a panel of experts, can offer a responsible and
safe approach to this medical and social problem (Manchikanti
et al., 2017). Moreover, the possible use of non-opioid drugs
such as NSAIDs, anticonvulsants, or antidepressants should
be considered for single cases verifying effectiveness and side
effects. Nevertheless, the possibility of directly intervening in
the mechanisms of the vicious cycle of tolerance development –
dose increase – side effects and abuse remains an attractive
approach.
The natural fatty-acid ethanolamide N-Palmitoylethanol-
amine (PEA), the endogenous amide between palmitic acid
and ethanolamine, was recently identified as an endogenous
molecule that intervenes with nervous alterations that lead to
the lack of morphine antinociceptive effects (Di Cesare Mannelli
et al., 2015a). In rats, PEA delayed the onset of morphine
analgesic tolerance by preventing the activation of glial cells
in the central nervous system, major players in the complex
phenomenon of tolerance (Mika, 2008; Mika et al., 2009).
Moreover, PEA protects nervous tissue in neuropathic conditions
(Di Cesare Mannelli et al., 2013a), prevents neurotoxicity and
neurodegeneration (Lambert et al., 2001; D’Agostino et al., 2012;
Esposito et al., 2012), and inhibits peripheral inflammation and
mast cell degranulation (Mazzari et al., 1996; Skaper et al.,
2013). PEA decreases hyperalgesia without altering the normal
pain threshold (Luongo et al., 2013; Di Cesare Mannelli et al.,
2015b).
Considering the theoretical bases for a possible application of
PEA in opioid-based therapies, we aim to define a preclinical
protocol for PEA supplementation of morphine repeated
treatment, focusing on the maintenance of a constantly high pain
threshold over time with low opioid dosage.
MATERIALS AND METHODS
Animals
For all the experiments described below, male Sprague-Dawley
rats (body weight 200–250 g; Harlan, Varese, Italy) were used.
Animals were housed in CeSAL (Centro Stabulazione Animali da
Laboratorio, University of Florence) and used at least 1 week after
their arrival. Four rats were housed per cage (size 26 cm× 41 cm)
kept at 23 ± 1◦C with a 12 h light/dark cycle (light at 7 a.m.),
and were fed a standard laboratory diet and tap water ad libitum.
All animal manipulations were carried out according to the
Directive 2010/63/EU of the European parliament and of the
European Union council (22 September, 2010) on the protection
of animals used for scientific purposes. The ethical policy of
the University of Florence complies with the Guide for the
Care and Use of Laboratory Animals of the United States
National Institutes of Health (NIH Publication No. 85-23, revised
1996; University of Florence Assurance No. A5278-01). Formal
approval to conduct the experiments described was obtained
from the Animal Subjects Review Board of the University of
Florence. Experiments involving animals have been reported
according to ARRIVE guidelines (McGrath and Lilley, 2015). All
efforts were made to minimize animal suffering and to reduce the
number of animals used.
Treatments
In the first phase experiments (Figures 1–3), ultramicronized
PEA (Epitech Group, Padova, Italy – 30 mg/kg suspended in 1%
carboxymethylcellulose) or vehicle were administered p.o. daily
(in the evening) from day −8 to day 0 and from day 1 to the end
of the experiment. Starting on day 1, up to the development of
tolerance, acute treatments with morphine (S.A.L.A.R.S., Como,
Italy – 10 mg/kg solubilized in 0.9% NaCl s.c.) were performed
in the morning, 16 h after PEA. Measurements of pain threshold
(Paw pressure test) were performed before (0 min) and 30 min
after morphine injection. Tolerance was considered established
the first day of complete loss of morphine antinociceptive
effect (day 7, for vehicle + morphine and 1 mg/kg PEA +
morphine groups; day 12, for 10 and 30 mg/kg PEA+morphine
groups). Restoration of morphine efficacy was tested 4, 10,
14, 21, and 31 days post onset of morphine tolerance (d.p.t.)
separately in each group. Also during this period, preemptive
PEA treatment was performed daily in the evening (10 or
30 mg/kg), and Paw pressure test was performed in the morning
16 h after PEA administration and 30 min after morphine
injection (10 mg/kg s.c.). The antinociceptive effect of acute PEA
(Figure 3) was evaluated in morphine tolerant rats 4 d.p.t.
Experiments carried out in the second phase (Figures 4, 5),
were performed on different groups treated, respectively, with
vehicle (group a) or PEA (30 mg/kg; groups b, c, and d)
p.o. daily (in the evening) for the duration of the experiment
starting on day −8. To maintain a significant increase of
pain threshold (90 ± 10 g) vs. baseline (control), beginning
on day 1, daily increasing doses of morphine (5–100 mg/kg)
were injected s.c. to groups a and b. Different combinations
of morphine (5–20 mg/kg, s.c.) and PEA (30–120 mg/kg, p.o.)
were administered to groups c and d. Control groups were
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FIGURE 1 | Effect of repeated administrations of PEA on the onset of morphine tolerance. PEA (1–30 mg/kg), or vehicle, was administered p.o. daily (in the evening)
for the duration of the experiment starting on day −8. On day 1, daily, acute morphine treatment (10 mg/kg s.c.) began. Pain threshold measurements (Paw pressure
test) were performed in the morning, 16 h after PEA administration and 30 min after morphine injection. Data are expressed as mean ± SEM of values from 12 rats
analyzed in two different experimental sets. ∗P < 0.05 and ∗∗P < 0.01 vs. vehicle + vehicle; ◦P < 0.05 and ◦◦P < 0.01 vs. vehicle + morphine.
FIGURE 2 | Effect of PEA on recovery from morphine tolerance. PEA (10 and 30 mg/kg), or vehicle, was administered p.o. daily (in the evening) for the duration of
the experiment starting on day −8. Beginning on day 1, each group was treated daily with morphine (10 mg/kg s.c.). Representatively, the effect obtained on day 3 is
shown (gray highlighted bars), the dashed line allows the comparison with the effects reached in the following days. Morphine treatment was continued till complete
loss of antinociceptive response. The restoration of morphine efficacy was tested 4, 10, 14, 21, and 31 days post morphine tolerance onset (d.p.t.) in each group,
respectively. Pain threshold measurements (Paw pressure test) were performed in the morning, 16 h after PEA administration and 30 min after morphine injection.
Data are expressed as mean ± SEM of values from 12 rats analyzed in two different experimental sets. ∗P < 0.05 and ∗∗P < 0.01 vs. vehicle + vehicle; ◦P < 0.05
and ◦◦P < 0.01 vs. vehicle + morphine.
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FIGURE 3 | Effect of acute administration of PEA in morphine-tolerant animals. Rats were treated with vehicle or PEA (30 mg/kg) p.o. daily (in the evening) for the
duration of the experiment starting on day −8. Morphine (10 mg/kg s.c.) was injected from day 1 till complete loss of antinociceptive response. When tolerance was
well-established (4 d.p.t.), pain threshold (Paw pressure test) was measured in the morning before (0 min) and 30 min after an acute treatment with PEA (30 mg/kg,
p.o.). Data are expressed as mean ± SEM of values from 12 rats analyzed in two different experimental sets. ∗P < 0.05 and ∗∗P < 0.01 vs. vehicle + vehicle, 30 min.
pre- and acutely treated with PEA (group e, PEA + vehicle +
PEA) or vehicle (group d, vehicle + vehicle + vehicle) without
morphine injections. Pain measurements were performed on
days 1–17, in the morning 30 min after morphine and/or PEA
acute administration.
Paw-Pressure Test
The nociceptive threshold of rats was determined with an
analgesimeter (Ugo Basile, Varese, Italy), according to the method
described by Leighton et al. (1988). A constantly increasing
pressure was applied to a small area of the dorsal surface of
the hind paw using a blunt conical probe by a mechanical
device. While rats were lightly restrained, mechanical pressure
was increased until vocalization or a withdrawal reflex occurred.
Vocalization or withdrawal reflex thresholds were expressed in
grams. Rats scoring below 40 g or over 75 g during the test
before drug administration were rejected (25%). For analgesia
measurements, mechanical pressure application was stopped
at 200 g.
Irwin Test
Each rat was individually placed in a transparent cage
(26 cm × 41 cm), and 26 neurobehavioral or physiological
parameters were systematically assessed according to Irwin
(1968). Behavioral, autonomic, and neurological manifestations
produced by compound administration in rats were evaluated:
motor displacement, motor reflexes, stereotypies, grooming,
reaction to painful or environmental stimuli (analgesia,
irritability), startle response, secretions, excretions, respiratory
movements, skin color and temperature, piloerection,
exophthalmos, eyelid and corneal reflexes, muscle tone, ataxia,
tremors, head twitches, jumps, convulsions, Straub tail, and
other signs or symptoms. For postural reflexes (righting reflex)
and other signs such as piloerection, exophthalmia (exaggerated
protrusion of the eyeball), ataxia, tremors, and Straub tail, only
presence or absence was recorded. Skin color was evaluated
qualitatively (pale, red, or purple); other signs were evaluated
semi-quantitatively, according to the observer’s personal scale
(0 to +4, −4 to 0, or −4 to +4). The terms sedation and
excitation express the final interpretation of a group of signs:
reduced motor activity, reduced startle response, eyelid ptosis,
and reduced response to manual manipulation with regard to the
former; and increased motor activity, increased startle response,
increased response to manual manipulation, and exophthalmia
with regard to the latter. Hyperactivity included running, jumps,
and attempts to escape from the container.
Statistical Analysis
Trained observers, not informed about the specific treatment of
each animal group carried out the tests. Results were expressed
as means ± SEM and analysis of variance was performed by
ANOVA test. A Bonferroni’s significant difference procedure was
used as a post hoc comparison. P-values less than 0.05 were
considered significant. Data were analyzed using “Origin 8.1”
software.
RESULTS AND DISCUSSION
The capacity of PEA to modulate the protective responses
against different damages to the nervous tissue proposes this
endogenous molecule as a component of the cellular homeostatic
system (Skaper et al., 2013). In some pathological conditions,
PEA endogenous production seems to be inadequate leading
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FIGURE 4 | Antinociceptive effects of different combinations of morphine and PEA. Rats were treated with vehicle (group a) or PEA (30 mg/kg; groups b, c, and d)
p.o. daily (in the evening) for the duration of the experiment starting on day −8. To maintain a significant increase of pain threshold (90 ± 10 g) vs. baseline (control;
indicated with the red line), beginning on day 1, increasing daily doses of morphine (5–100 mg/kg) were injected s.c. to groups a and b. Different combinations of
morphine (5–20 mg/kg, s.c.) and PEA (30–120 mg/kg, p.o.) were administered to groups c and d. Measurements were performed every day, in the morning, 30 min
after morphine and/or PEA acute administration. Representative results obtained on days 1, 4, 8, 12, and 17 are shown. Data are expressed as mean ± SEM of
values from 12 rats analyzed in two different experimental sets. ∗P < 0.05 and ∗∗P < 0.01 vs. the normal pain threshold (control, vehicle + vehicle + vehicle);
◦P < 0.05 and ◦◦P < 0.01 vs. group a.
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FIGURE 5 | Comparison among equi-analgesic dosages of morphine/PEA combinations and morphine. Rats were treated with vehicle (group a) or PEA (30 mg/kg;
groups c and d) p.o. daily (in the evening) for the duration of the experiment starting on day −8. To maintain a significant increase of pain threshold (90 ± 10 g),
beginning on day 1, increasing daily doses of morphine (5–100 mg/kg) were injected s.c. to group a. Different combinations of morphine (5–20 mg/kg, s.c.) and PEA
(30–120 mg/kg, p.o.) were administered to groups c and d. The dosages in mg/kg necessary to maintain the required antinociceptive effect every day (Paw pressure
test; days 1–17) are reported. Measurements were performed in the morning, 30 min after morphine and/or PEA acute administration. Each group consists of 12
rats analyzed in two different experimental sets.
to the need for exogenous supplementation. In order to favor
the homeostatic processes mediated by PEA, we decided to
explore the effect of PEA pretreatment on morphine analgesia
and tolerance development. Rats were treated with PEA
(1–30 mg/kg, p.o.) daily (in the evening) from day −8 for the
duration of the experiment (day 12). On day 1 (16 h after the
last PEA administration), morphine (10 mg/kg s.c.) was injected.
Thirty minutes later, the pain threshold was measured by Paw
pressure test. The pretreatment with PEA dose-dependently
increased the responsiveness to morphine (Figure 1): animals
tolerated 171.7 ± 14.2 g (30 mg/kg PEA + morphine) on
the posterior paw in comparison to 128.6 ± 5.2 g (vehicle
+ morphine) starting from a basal value of 67.2 ± 0.3 g
(vehicle + vehicle). In the following days, morphine efficacy
progressively decreased. On day 7, vehicle + morphine-treated
animals completely lacked the analgesic response whereas rats
pretreated with PEA and morphine exhibited a delay in the
onset of tolerance till day 12 (Figure 1). Interestingly, the
extension of morphine response was promoted by PEA also
in the absence of the pretreatment (as previously published,
Di Cesare Mannelli et al., 2015a), instead pretreatment is
necessary to increase morphine efficacy in the first days. On
the other hand, the modulatory role mediated by PEA on mast
and glial cells as well as on receptor signaling [peroxisome
proliferator-activated receptor (PPAR)-α; cannabinoid; Di Cesare
Mannelli et al., 2015b] can promote phenomena of cellular
plasticity able to enhance morphine analgesia after a repeated
treatment in naïve animals. The same groups were monitored
over time to assess the recovery from tolerance measuring the
responsiveness to morphine. During the recovery period, PEA-
treated animals continued to receive the compound daily (10
and 30 mg/kg) whereas control groups were treated with vehicle.
Morphine (10 mg/kg) was injected on selected days. As shown in
Figure 2, 4 days post tolerance development (d.p.t., tolerance was
considered as the complete lack of morphine effect, separately for
each group), PEA-treated groups had already regained sensitivity
to morphine (Paw pressure test, 30 min after injection). At least
for the higher dosed group (30 mg/kg PEA), the antinociceptive
effect was registered also on 10, 14, 21, 31 d.p.t. The lower dose
did not seem to be able to sustain a stable effect. Control rats
treated with vehicle exhibited recovery from tolerance 31 d.p.t.
only (Figure 2, vehicle+morphine). After recovery of tolerance,
no treatment group reached the full analgesic effects obtained on
day 1. Nevertheless, PEA-treated animals showed antinociception
as intense as morphine on day 3 before the onset of tolerance
(Figure 2, dashed line).
As previously published, PEA counteracts pain
hypersensitivity without modifying the normal nociception
(Luongo et al., 2013; Di Cesare Mannelli et al., 2015b).
Conditions of hypersensitivity, like neuropathic pain, share
common characteristics with opioid tolerance. Among others,
the plasticity of glial cells is present in both conditions (Mika,
2008; Di Cesare Mannelli et al., 2013b, 2014) whereas glial
inhibitors like minocycline or fluorocitrate attenuate both
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morphine tolerance and neuropathic pain (Mika et al., 2009;
Di Cesare Mannelli et al., 2014). PEA is a modulator of the
glial response (Skaper et al., 2013; Di Cesare Mannelli et al.,
2015a) and is active against neuropathic pain (Di Cesare
Mannelli et al., 2013a) so we were excited to evaluate the
effect of PEA in morphine tolerant rats. Different groups were
treated daily (in the evening) p.o. with PEA (30 mg/kg) or
vehicle; morphine (10 mg/kg s.c.) was injected from day 1 till
the complete loss of antinociceptive response was reached.
When tolerance was well-established (4 d.p.t. for each group),
the pain threshold (Paw pressure test) was measured in the
morning before (0 min) and 30 min after an acute treatment
with PEA (30 mg/kg, p.o.). Figure 3 shows the expected lack
of antinociceptive effect of PEA in control (vehicle + vehicle)
as well as in the morphine-tolerant rats pretreated with vehicle.
On the contrary, the morphine-tolerant rats pretreated with
PEA exhibited antinociception upon its acute administration,
as evidenced by an increase in pain threshold up to 86.3 ± 4.1 g
(30 min; in comparison to 64.9 ± 1.2 g, pretest value at
0 min).
On the basis of this evidence, we decided to set up a preclinical
protocol focused on maintaining of a stable antinociception
based on the use of preemptive PEA followed by the acute
association of morphine and PEA. The purpose was to obtain
daily, over time, the same increase of pain threshold (arbitrarily
fixed at 90 ± 10 g, as measured by Paw pressure, starting from
a basal value of about 65 ± 5 g) using the lowest possible
morphine dosages. Rats were treated with vehicle (group a) or
PEA (30 mg/kg; groups b, c, and d) p.o. daily (in the evening)
for the duration of the experiment starting on day −8. From
day 1 till day 17, daily pain measurements were performed in
the morning (16 h after the last preemptive PEA administration),
before and 30 min after an acute treatment with increasing doses
of morphine (5–100 mg/kg, s.c., groups a and b) or different
combinations of morphine (5–20 mg/kg, s.c.) and PEA (30–
120 mg/kg, p.o.) (groups c and d). Day by day results are
shown in the Supplementary Figures S1A–D. Figure 4 shows
the results of representative days. On day 1, 5 mg/kg morphine
s.c. increased the pain threshold of group a to 87.2 ± 1.1 g.
As expected, the other groups pretreated with PEA showed
higher responses to morphine, reaching about 110 g. On day
4, 10 mg/kg morphine was needed to maintain antinociception
up to about 90 g (group a) whereas 5 mg/kg were enough for
group b. The combination of 5 mg/kg morphine and 30 mg/kg
PEA boosted the increase up to about 110 g. On day −8,
16 mg/kg morphine was active in group a, 10 mg/kg induced
higher effects in groups b and c (preemptive PEA), and only
7 mg/kg morphine were necessary when combined with 30 mg/kg
PEA. On day 12, the acute administration of 7 mg/kg morphine
associated with 90 mg/kg PEA (group d) evoked a better effect
than 20 mg/kg morphine alone (group a). Interestingly, as further
described in Figure 3, also the acute administration of 30 mg/kg
PEA alone induced a modest but significant effect (group c).
On day 17, a dramatic increase of morphine (100 mg/kg) was
needed to induce a significant effect in groups a and b, and PEA
association allowed efficacy using 20 mg/kg morphine/90 mg/kg
PEA or 13 mg/kg morphine/120 mg/kg PEA in groups c and
d, respectively. The same tests were conducted on a group pre-
(30 mg/kg) and acutely- (30–120 mg/kg) treated with PEA alone
(group e). As shown in Supplementary Table S1, the pain
threshold of these animals was not modified by administration
of PEA. Moreover, the pain threshold of each groups (a–e) was
not significantly different at the pretest performed every day
(0 min) before acute administration (Supplementary Table S2).
Similar values (about 65 g) were shown by the control group
that received vehicle + vehicle treatments (group f; data not
shown).
Figure 5 summarizes the results showing the trend of dosage
increase (days 1–17) to obtain a significant antinociception
(90 ± 10 g) in group a (preemptive vehicle + acute morphine
+ acute vehicle) in comparison with groups c and d (preemptive
PEA + acute morphine + acute PEA). The doses of acutely
administered morphine and PEA are reported.
Finally, the good tolerability of PEA is described in several
clinical studies (Kahlich et al., 1979; Mazzari et al., 1996;
Keppel Hesselink et al., 2013). Accordingly, the present data
showed that the repeated treatment with increasing doses of PEA
(group e) did not induce behavioral, autonomic or neurological
alteration as evaluated by the Irwin test (Supplementary
Table S3).
Our results agree with a modulatory role of the natural lipid
PEA in the nervous system. The pharmacodynamic involves
receptor-mediated signals as the activation of the α-subtype
(and, lesser, the δ and γ subtypes; Paterniti et al., 2013) of the
peroxisome proliferator-activated receptors able to evoke pain
relief and neurorestoration (LoVerme et al., 2006; Di Cesare
Mannelli et al., 2013a), and endocannabinoid-driven actions
(on the basis of a PEA-mediated enhancement of endogenous
compounds by potentiating their affinity for receptors or by
inhibiting their metabolic degradation; Calignano et al., 1998).
Moreover, PEA increases the antioxidant defense (Mattace Raso
et al., 2013) and exerts antiinflammatory effects (enhancement
of IκB-α, decrease of COX-2 in the spinal cord; Di Cesare
Mannelli et al., 2015b), counteracting two characteristic features
of morphine tolerance development (Abdel-Zaher et al., 2013;
Eidson et al., 2017). Redox imbalance (Abdel-Zaher et al., 2013)
and inflammation (Eidson et al., 2017) decrease the analgesic
effects of morphine whereas endocannabinoids (Wilkerson et al.,
2017) and PPARs (at least for the γ-subtype; de Guglielmo
et al., 2014) modulations are positive regulators of morphine
antinociception.
Moreover, acute and chronic morphine evokes a CNS glial
cell response that actively opposes the analgesic effects of
morphine and contributes to the development of tolerance
(Eidson and Murphy, 2013). Repeated morphine treatments
activate microglia and astrocyte cells, enhancing density and
favoring cell hypertrophy. On the contrary, administration of
pharmacological glial inhibitors attenuates tolerance to morphine
analgesia (Song and Zhao, 2001; Mika, 2008; Mika et al.,
2009). Interestingly, PEA seems to be able to modulate glial
cells instead to act as a general depressor of glial functions
(Skaper et al., 2013). The homeostatic properties of PEA may
allow the inhibition of glial hyper-reactivity, thus PEA prevents
microglia and astrocyte activation in models of inflammatory
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and neuropathic pain (Esposito et al., 2011; Luongo et al., 2013;
Di Cesare Mannelli et al., 2015b). Recently, we demonstrated
the property of PEA of attenuating morphine tolerance by a
glia-mediated mechanism (Di Cesare Mannelli et al., 2015a).
Interestingly, the Nobel prize winner Rita Levi-Montalcini
suggested PEA as an autacoid negatively modulating the behavior
of mast cells in response to noxious stimuli [autacoid local
inflammation antagonism (ALIA); Aloe et al., 1993]. PEA
reduces mast cell degranulation controlling CNS damages by
limiting mast cell infiltration and activation (Skaper et al.,
2013). The increased number of mast cells could increase the
blood brain barrier (BBB) permeability and activate microglia,
astrocytes, and T cells (Kempuraj et al., 2017). Mast cells are
resident in the CNS (Skaper et al., 2015), and are also able
to cross the BBB into the brain from the peripheral tissue
in neuroinflammatory conditions (Florenzano and Bentivoglio,
2000; Skaper et al., 2012; Silver and Curley, 2013) as well
as in physiological conditions (Silverman et al., 2000). The
key mast cell mediator, histamine, has sensitizing effects on
nociceptors, as well as other soluble factors secreted by
mastocytes. Mast cell degranulation is a principal source of
rapid release of proalgic nerve growth factor (NGF), and mast
cells respond in a paracrine/autocrine fashion to NGF (Skaper
et al., 2013). The capacity of PEA to modulate protective
responses during inflammation and pain led to the hypothesis
that endogenous PEA may be a component of the complex
homeostatic system controlling the basal threshold of pain.
In 2014, opioids were involved in about 30000 deaths in
the United States, mostly related to natural and semisynthetic
opioids, a tripling of the rate of opioid overdoses compared
to 2000 (Rudd et al., 2016a,b; Manchikanti et al., 2017). Data
from the Centers for Disease Control and Prevention show
that the United States’ opioid overdose epidemic includes an
increase in overdose deaths involving prescription opioid pain
relievers (Rudd et al., 2016a,b). The problem is mainly related to
treatment of persistent pain based on increasing doses of opioids.
Systematic assessment of evidence showed that opioid doses of
200 morphine milligram equivalents (MME) per day increased
mortality rates gradually, higher than the doses of 100 MME
or more per day, increasing the risks for opioid overdose by
factors of 2.0 to 8.9 (Dasgupta et al., 2016; Manchikanti et al.,
2017).
The present results suggest PEA as a powerful enhancer
of morphine antinociception able to allow maintenance of
low dosages and long-lasting activity, attenuating tolerance
development. This preclinical approach is proposed for a clinical
validation facilitated by PEA safety profile.
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FIGURE S1 | (A,B) Induction of antinociception over time with different
combinations of morphine and PEA. Rats were treated with vehicle (group a) or
PEA (30 mg/kg; groups b, c, and d) p.o. daily (in the evening) for the duration of
the experiment starting on day −8. To maintain a significant increase of pain
threshold (90 ± 10 g) vs. baseline (control; vehicle + vehicle + vehicle, not
shown), beginning on day 1, increasing daily doses of morphine (5–100 mg/kg)
were injected s.c. to groups a and b. Measurements were performed on days
1–17, in the morning 30 min after morphine and/or PEA acute administration.
Data are expressed as the mean ± SEM of values from 12 rats analyzed in two
different experimental sets. (C,D) Rats were treated with PEA (30 mg/kg; groups c
and d) p.o. daily (in the evening) for the duration of the experiment starting on day
−8. To maintain a significant increase of pain threshold (90 ± 10 g) vs. baseline
(control; vehicle + vehicle + vehicle, not shown), beginning on day 1, different
daily combinations of morphine (5–100 mg/kg, s.c.) and PEA (30–120 mg/kg,
p.o.) were administered to groups c and d. Measurements were performed on
days 1–17, in the morning 30 min after morphine or/and PEA acute
administration. Data are expressed as mean ± SEM of values from 12 rats
analyzed in two different experimental sets.
TABLE S1 | Effect of repeated treatments with PEA on the pain threshold
measured by the Paw pressure test.
TABLE S2 | Induction of anti-nociception over time with different combination of
morphine and PEA Paw pressure test.
TABLE S3 | Effect of repeated treatments with PEA on behavioral, autonomic, and
neurological manifestations by the Irwin test.
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